National Brain Tumor Society Invests in GBM AGILE, the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
65
National Brain Tumor Society Invests in GBM AGILE, the World’s First Global Adaptive Trial for Glioblastoma Brain Cancer

Boston, MA, Jan. 16, 2019 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS) , the largest nonprofit dedicated to the brain tumor community in the United States, today announced a partnership with the  Global Coalition for Adaptive Research (GCAR) , a nonprofit organization comprised of some of the world’s foremost clinical, translational, and basic science investigators. NBTS has provided GCAR with a $750,000 award to help launch and build patient awareness of the world’s first global “adaptive” clinical trial for brain cancer, GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).

“The past decade of scientific advances has moved glioblastoma research to a pivotal point which calls for a platform like GBM AGILE to get potentially breakthrough medicines to patients – who can’t afford to wait – faster than standard clinical trial designs,” said David Arons, Chief Executive Officer, National Brain Tumor Society. “GBM AGILE is a ‘game-changer’ for neuro-oncology and is an opportunity for NBTS to collaborate with multiple stakeholders in the brain tumor field to revolutionize the future for patients. This trial also represents the spirit of the NBTS  Defeat GBM Research Collaborative  program, which was specifically designed to accelerate precision medicine research and take more ‘shots on goal’ by supporting opportunities to find treatments and a cure for the most deadly and aggressive type of brain tumor, glioblastoma.”

GBM AGILE is designed as a learning system to more efficiently and rapidly identify effective therapies for glioblastoma (GBM). GBM AGILE’s innovative model enables multiple drugs (and combinations of drugs) to be screened simultaneously and over time. Drugs that show initial evidence of benefit to patients will seamlessly transition to a  confirmatory stage designed to support registration approval . Drugs that are underperforming are dropped. The intent is to lower the cost, time, and number of patients required to evaluate potentially new effective therapies for patients with GBM.

“We are proud to partner with the National Brain Tumor Society, one of the most respected voices in the GBM community,” said Brian Alexander, M.D., M.P.H., Co-founder of GCAR. “As one of the original champions of GBM AGILE, we want to recognize NBTS’s early contributions to the trial design. GCAR is deeply grateful for their confidence, financial support to help launch the trial, and devotion and continued commitment to finding better treatments for this devastating disease.”

“I’m honored to welcome the National Brain Tumor Society as a collaborator and funder to the GBM AGILE platform and am excited in the knowledge that, together, we’re taking a major step toward getting new, more personalized treatments to patients faster,” said Faramarz Yousefzadeh, Chairman of the GCAR Board of Directors, who lost his wife to brain cancer. “I hope many others will follow NBTS’s lead in supporting this important trial so we can conquer brain tumors once and for all.”

In late 2018,  GCAR announced a partnership with Bayer Oncology  to include the company’s drug regorafenib as the first therapy entering the GBM AGILE platform which will begin in early 2019. Ultimately, the trial will include multiple arms at clinical sites throughout the United States, Canada, and Australia, expanding into Europe and Asia, in the near future.

GBM AGILE was first conceived in 2015 by an international group of more than 130 clinicians, researchers, biostatisticians, imagers, pathologists, patient advocates, and leaders from government and industry. NBTS co-sponsored and participated in the early planning meetings, including co-chairing the original GBM Advocates Committee, while the trial was still in its early development stages under the management of the National Biomarker Development Alliance and Dr. Anna Barker of Arizona State University. Many of  GCAR and GBM AGILE’s leaders  also serve in numerous advisory roles to NBTS, including Dr. Alfred Yung of MD Anderson, who currently is the organization’s Distinguished Research Advisor, and Dr. Webster Cavenee of Ludwig Cancer Research, who serves on the Strategic Scientific Advisory Council for the Defeat GBM Research Collaborative.

Visit  http://www.gcaresearch.org/gbm-agile  for more about GBM AGILE.

About National Brain Tumor Society National Brain Tumor Society invests in, mobilizes, and unites the brain tumor community to discover a cure, deliver effective treatments, and advocate for patients and care partners. We are the largest patient advocacy non-profit solely dedicated to the brain tumor community and a leading thought leader in the neuro-oncology field. Headquartered in Newton, Massachusetts, our organization raises funds to invest in accelerating brain tumor treatments, prepare the community to navigate their unique brain tumor experience, and convene stakeholders while changing public policy to improve the lives and survival of brain tumor patients. Visit us at  https://braintumor.org .

About Global Coalition for Adaptive Research The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) non-profit charitable organization, comprised of some of the world’s foremost physicians, clinical researchers and investigators united in expediting the discovery and development of cures for patients with rare and deadly diseases. As its first priority, GCAR is sponsoring GBM AGILE, an adaptive platform trial for patients with glioblastoma (GBM) – the most common and deadliest of malignant primary brain tumors. It is GCAR’s vision is to expand and replicate what is learned using this innovative model for glioblastoma to benefit patients with other rare and deadly diseases. To learn more about GCAR, visit  www.gcaresearch.org  and follow us at @GCAResearch and www.facebook.com/GCAResearch.

Tom Halkin Senior Manager of Communications National Brain Tumor Society Phone: (617) 393-2849 E-Mail: thalkin@braintumor.org Michael Antonellis Chief Marketing Officer National Brain Tumor Society Phone: (617) 393-2841 E-Mail: mantonellis@braintumor.org

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 153

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 219

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 197

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 118

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Organizations: RockDove Solutions on Crisis Communication

Updated Category News Views 111

Understanding the Importance of Crisis Communication Plans In today's fast-paced world, effective crisis communication is more critical than ever for businesses. Surprisingly, fewer than half of U.S. companies have formal crisis communication strategies in place. This statistic highlights a significant gap in business continuity planning, where communication often...

Continue Reading
Hafnia Limited Reports Strong Earnings for Q3 2024 Period

Updated Category News Views 83

Hafnia Limited Reports Strong Earnings for Q3 2024 Period Hafnia Limited (“Hafnia” or “the Company”, OSE ticker code: “HAFNI”, NYSE ticker code: “HAFN”), a premier product tanker company with an extensive and modern fleet exceeding 130 vessels, has recently reported promising financial results for the three and nine months ended September 30, 2024. Key...

Continue Reading
Recent Shareholding Changes at Irish Continental Group PLC

Updated Category News Views 138

Understanding Director and PDMR Shareholding Notifications In the world of corporate governance, transparency plays a crucial role in maintaining trust, particularly when it comes to senior management and directors. Recent notifications reveal key transactions involving persons discharging managerial responsibilities (PDMRs) at Irish Continental Group plc. Overview of...

Continue Reading
Experience the Summer Vibes at Coastal Mississippi Events

Updated Category News Views 220

Summer Events in Coastal Mississippi Come Play Coastal all summer long with seafood feasts, fireworks, car shows, and more! Ready to turn up the fun this summer? Coastal Mississippi is bringing a thrilling lineup of unforgettable events, all set against the backdrop of 62 miles of beautiful shoreline. From fresh seafood to electrifying fireworks, sensational car shows,...

Continue Reading
GUNNAR Optiks and 2K Games Unveil Exciting New Glasses

Updated Category News Views 197

GUNNAR Optiks Partners with 2K Games for New Glasses GUNNAR Optiks, a frontrunner in combating digital eye strain and a pioneer in blue light blocking eyewear, has teamed up with 2K Games to introduce an exciting new collection inspired by the much-anticipated Borderlands 4. This striking collection unveils its first eyewear style, aptly named the Ripper, marking the...

Continue Reading